LifeStance Health Group, Inc. (NASDAQ:LFST) Receives Average Recommendation of "Buy" from Brokerages

Key Points

• Nine analysts give LifeStance a consensus recommendation of Buy with an average 12‑month price target of $9.83, and several firms (including UBS, BTIG, Canaccord and Barclays) recently raised their targets.
• The company reported a Q1 beat—$403.5M revenue (+21% YoY) and $0.04 EPS—then raised Q2 and FY2026 revenue guidance and its board authorized a concurrent repurchase of up to 6M shares alongside an existing $100M buyback plan.
• Insiders and selling stockholders have been heavy sellers (insiders sold ~4.39M shares in the last three months) and a planned 35M‑share secondary offering by existing holders creates near‑term supply and volatility risk despite the buyback actions.

LifeStance Health Group, Inc. (NASDAQ:LFST - Get Free Report) has been assigned a consensus recommendation of "Buy" from the nine analysts that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $9.8333.

A number of equities analysts recently weighed in on the stock. Barclays boosted their price objective on shares of LifeStance Health Group from $8.00 to $9.00 and gave the stock an "overweight" rating in a report on Friday, March 6th. BTIG Research lifted their target price on shares of LifeStance Health Group from $10.00 to $11.00 and gave the stock a "buy" rating in a research report on Monday, February 2nd. Canaccord Genuity Group lifted their target price on shares of LifeStance Health Group from $9.00 to $10.00 and gave the stock a "buy" rating in a research report on Thursday, February 26th. UBS Group lifted their target price on shares of LifeStance Health Group from $10.00 to $12.00 and gave the stock a "buy" rating in a research report on Thursday, February 26th. Finally, Wall Street Zen raised shares of LifeStance Health Group from a "hold" rating to a "buy" rating in a research report on Sunday, February 8th.

Insiders Place Their Bets

In other news, Director Robert Bessler sold 62,147 shares of the business's stock in a transaction on Friday, April 24th. The shares were sold at an average price of $7.05, for a total transaction of $438,136.35. Following the completion of the sale, the director owned 1,274,448 shares of the company's stock, valued at $8,984,858.40. The trade was a 4.65% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Darren M. Black sold 4,314,939 shares of the business's stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $7.01, for a total transaction of $30,247,722.39. Following the sale, the director directly owned 29,209,776 shares of the company's stock, valued at approximately $204,760,529.76. The trade was a 12.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 4,389,939 shares of company stock valued at $30,775,881. Insiders own 3.20% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Vanguard Group Inc. lifted its stake in shares of LifeStance Health Group by 21.1% during the 4th quarter. Vanguard Group Inc. now owns 17,700,041 shares of the company's stock valued at $124,608,000 after buying an additional 3,086,506 shares in the last quarter. Silversmith Partners I GP LLC purchased a new position in shares of LifeStance Health Group during the 4th quarter valued at $100,842,000. Dimensional Fund Advisors LP lifted its stake in shares of LifeStance Health Group by 16.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 10,367,680 shares of the company's stock valued at $66,038,000 after buying an additional 1,461,215 shares in the last quarter. Jennison Associates LLC lifted its stake in shares of LifeStance Health Group by 38.5% during the 1st quarter. Jennison Associates LLC now owns 10,228,801 shares of the company's stock valued at $65,157,000 after buying an additional 2,843,388 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of LifeStance Health Group by 27.6% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 6,118,027 shares of the company's stock valued at $43,071,000 after buying an additional 1,324,691 shares in the last quarter. Hedge funds and other institutional investors own 85.50% of the company's stock.

Key Stories Impacting LifeStance Health Group

Here are the key news stories impacting LifeStance Health Group this week:

• Positive Sentiment: Q1 beat — LifeStance reported Q1 revenue of $403.5M (up ~21% YoY) and EPS of $0.04, both above consensus, which is driving the bullish reaction. Read More.
• Positive Sentiment: Raised revenue guidance — Management updated Q2 and FY2026 revenue ranges above Street revenue expectations (Q2: $405M–$425M; FY: ~$1.6B–$1.7B), supporting the stock rally by signaling continued top-line growth. Read More.
• Positive Sentiment: Board authorized a concurrent repurchase of up to 6M shares — the buyback can partially offset selling pressure from the secondary and is being highlighted as shareholder-friendly. Read More.
• Neutral Sentiment: Earnings call transcript and slide deck are available for detail — analysts and investors are parsing margins, clinician growth, and reimbursement commentary from the call. Read More.
• Negative Sentiment: Large secondary offering by existing stockholders: 35M shares will be sold by selling stockholders (LifeStance receives no proceeds). That raises near-term supply and volatility risk; heavy insider/related-party selling is noted in filings. Investors must weigh the selling pressure against the 6M-share repurchase. Read More. · Read More.

LifeStance Health Group Price Performance

Shares of NASDAQ LFST opened at $8.85 on Friday. LifeStance Health Group has a twelve month low of $3.74 and a twelve month high of $8.89. The firm has a market cap of $3.43 billion, a P/E ratio of 442.72 and a beta of 1.20. The company has a 50 day moving average of $6.80 and a 200 day moving average of $6.68. The company has a quick ratio of 1.65, a current ratio of 1.65 and a debt-to-equity ratio of 0.17.

LifeStance Health Group (NASDAQ:LFST - Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The company reported $0.04 earnings per share for the quarter, topping analysts' consensus estimates of $0.01 by $0.03. LifeStance Health Group had a net margin of 0.68% and a return on equity of 0.65%. The company had revenue of $403.48 million during the quarter, compared to analyst estimates of $387.46 million. LifeStance Health Group's revenue was up 21.2% on a year-over-year basis. As a group, research analysts expect that LifeStance Health Group will post 0.09 EPS for the current fiscal year.

LifeStance Health Group announced that its Board of Directors has initiated a share repurchase plan on Wednesday, February 25th that allows the company to buyback $100.00 million in shares. This buyback authorization allows the company to reacquire up to 3.6% of its shares through open market purchases. Shares buyback plans are generally an indication that the company's board of directors believes its stock is undervalued.

About LifeStance Health Group

LifeStance Health Group NASDAQ: LFST is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.